Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOFER N BUATTI

Allopathic & Osteopathic Physicians Dermatology

NPI
1306872288
CMS profile
149687
Location
AUBURN HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$12,392.28

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOFER N BUATTI

NPI 1306872288 · CMS profile ID 149687

Allopathic & Osteopathic Physicians / Dermatology

AUBURN HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306872288?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOFER N BUATTI, NPI 1306872288, CMS profile ID 149687. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306872288?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHRISTOFER N BUATTI, NPI 1306872288, CMS profile ID 149687. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306872288?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHRISTOFER N BUATTI, NPI 1306872288, CMS profile ID 149687, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1306872288?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $12,392.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $1.9307/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788098485 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $16.3507/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869767 CMS
Amgen Inc. $31.3307/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826313281 CMS
Lilly USA, LLC $19.9907/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819009241 CMS
Galderma Laboratories, L.P. $5.6707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265825 CMS
Galderma Laboratories, L.P. $0.7207/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265827 CMS
Janssen Biotech, Inc. $15.3407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788098471 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $16.8107/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869773 CMS
Allergan, Inc. $16.0007/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792719445 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $16.8106/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869763 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $0.9806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869769 CMS
Galderma Laboratories, L.P. $1.0406/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265821 CMS
Galderma Laboratories, L.P. $5.5306/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265823 CMS
Novartis Pharmaceuticals Corporation $13.1006/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812620863 CMS
Amgen Inc. $29.1506/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826313277 CMS
Galderma Laboratories, L.P. $3.7806/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265817 CMS
Galderma Laboratories, L.P. $2.3206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265819 CMS
LEO Pharma Inc. $17.0706/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151557 CMS
VYNE Pharmaceuticals Inc. $21.1306/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830816369 CMS
VYNE Pharmaceuticals Inc. $11.6706/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830816375 CMS
VYNE Pharmaceuticals Inc. $7.3306/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830824405 CMS
Janssen Biotech, Inc. $12.3306/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788098473 CMS
EPI Health, LLC $17.0406/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854623147 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.6406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869737 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.8706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869757 CMS
Amgen Inc. $7.6606/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826313265 CMS
Regeneron Healthcare Solutions, Inc. $24.4006/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562581 CMS
Galderma Laboratories, L.P. $3.9606/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265813 CMS
Galderma Laboratories, L.P. $5.9906/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265815 CMS
AbbVie Inc. $16.0706/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794176175 CMS
Amgen Inc. $26.6006/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826313273 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.6406/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869735 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.3006/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869741 CMS
VYNE Pharmaceuticals Inc. $1.0406/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830824401 CMS
VYNE Pharmaceuticals Inc. $15.6306/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830827457 CMS
Galderma Laboratories, L.P. $3.7805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265809 CMS
Galderma Laboratories, L.P. $10.0805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265811 CMS
LEO Pharma Inc. $18.4405/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151543 CMS
AbbVie Inc. $17.0405/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794176171 CMS
Janssen Biotech, Inc. $20.6705/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788098493 CMS
Janssen Biotech, Inc. $23.3005/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788098463 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.6405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869747 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $1.6605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869755 CMS
Amgen Inc. $1,250.0005/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826313261 CMS
Regeneron Healthcare Solutions, Inc. $16.6705/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562579 CMS
EPI Health, LLC $24.0805/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854623145 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $6.3405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869739 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $19.6405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851869753 CMS
Galderma Laboratories, L.P. $3.7805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855265807 CMS
AbbVie Inc. $15.0905/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794176167 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,271.47 314
PY2020 $18,391.54 271
PY2021 $12,392.28 232
PY2022 $27,012.76 210
PY2023 $60,948.68 296
PY2024 $50,508.62 272
PY2025 $31,796.43 199

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $212,462.41 117
PY2024 Principal investigator $413,191.07 93
PY2023 Recipient $25,390.00 2
PY2023 Principal investigator $173,394.98 42
PY2022 Recipient $605.00 2
PY2022 Principal investigator $173,595.73 14
PY2021 Recipient $13,337.00 5
PY2021 Principal investigator $172,106.20 21
PY2020 Principal investigator $226,783.97 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

117 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
OAKLAND HILL DERMATOLOGY
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202534793
Principal investigator 1 Incyte Corporation $5,053.50 12/19/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) No dispute reported 06/30/2026 1240567026
Principal investigator 1 PFIZER INC. $1,283.18 12/17/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228744012
Principal investigator 1 PFIZER INC. $570.00 11/19/2025 Non-covered Recipient Entity
Oakland Hills Dermatology P C
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228748436
Principal investigator 1 ABBVIE INC. $6,252.75 11/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202522877
Principal investigator 1 PFIZER INC. $1,202.18 10/29/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228742109
Principal investigator 1 SANOFI US SERVICES INC. $877.50 10/17/2025 Non-covered Recipient Entity
Oakland Hills Dermatology Pc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101903
Principal investigator 1 ABBVIE INC. $2,809.50 10/09/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202514269
Principal investigator 1 PFIZER INC. $2,257.20 10/06/2025 Non-covered Recipient Entity
Oakland Hills Dermatology
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228714979
Principal investigator 1 PFIZER INC. $2,404.36 09/19/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228770577
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,800.00 09/18/2025 Non-covered Recipient Entity
Oakland Hills Dermatology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235995034
Principal investigator 1 PFIZER INC. $1,069.88 09/12/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228750897
Principal investigator 1 PFIZER INC. $570.00 09/11/2025 Non-covered Recipient Entity
Oakland Hills Dermatology P C
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715153
Principal investigator 1 ABBVIE INC. $4,132.50 09/03/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202508250
Principal investigator 1 PFIZER INC. $4,202.56 08/23/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228789593
Principal investigator 1 Incyte Corporation $1,322.70 08/13/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567013
Principal investigator 1 Incyte Corporation $1,794.00 08/13/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567018
Principal investigator 1 ABBVIE INC. $3,849.00 08/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202502913
Principal investigator 1 PFIZER INC. $1,671.98 08/05/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766733
Principal investigator 1 PFIZER INC. $5,926.50 07/29/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781645
Principal investigator 1 PFIZER INC. $1,345.00 07/16/2025 Non-covered Recipient Entity
Oakland Hills Dermatology P C
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715155
Principal investigator 1 PFIZER INC. $1,345.00 07/16/2025 Non-covered Recipient Entity
Oakland Hills Dermatology P C
PRESTO CHARACTERIZATION AND CLINICAL OUTCOMES OF ALOPECIA AERATA AA PATIENTS TREATED WITH RITLECITINIB IN A REALWORLD RW COHORT A MULTINATIONAL PROSPECTIVE OBSERVATIONAL STUDY No dispute reported 06/30/2026 1228715157
Principal investigator 1 SANOFI US SERVICES INC. $877.50 07/11/2025 Non-covered Recipient Entity
Quality Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,142.12 07/09/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282466
Principal investigator 1 ABBVIE INC. $4,078.50 07/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202495749
Principal investigator 1 Incyte Corporation $1,502.10 06/20/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566983
Principal investigator 1 ABBVIE INC. $3,322.50 06/03/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202488795
Principal investigator 1 Incyte Corporation $1,691.10 05/14/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566989
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,090.00 05/13/2025 Non-covered Recipient Entity
Oakland Hills Dermatology
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1220807557
Principal investigator 1 ABBVIE INC. $9,008.25 05/07/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483903
Principal investigator 1 PFIZER INC. $2,518.43 05/03/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773290
Principal investigator 1 Incyte Corporation $61.23 05/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567447
Principal investigator 1 Incyte Corporation $3.11 05/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567458
Principal investigator 1 Incyte Corporation $68.70 05/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567464
Principal investigator 1 Incyte Corporation $52.48 05/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567473
Principal investigator 1 Incyte Corporation $58.15 05/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567482
Principal investigator 1 SANOFI US SERVICES INC. $74.25 04/23/2025 Non-covered Recipient Entity
Quality Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101355
Principal investigator 1 Incyte Corporation $1,724.40 04/16/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566999
Principal investigator 1 Incyte Corporation $1,806.30 04/11/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567005
Principal investigator 1 SANOFI US SERVICES INC. $877.50 04/11/2025 Non-covered Recipient Entity
Quality Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101363
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,055.00 04/11/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277950
Principal investigator 1 Eli Lilly and Company $15,675.30 04/10/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187887368
Principal investigator 1 ABBVIE INC. $6,185.25 04/03/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202469526
Principal investigator 1 Eli Lilly and Company $4,650.00 04/02/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
PSOSA (PSORIASIS SPECIAL AREAS) - A US-BASED, SINGLE-ARM, PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY OF NAIL AND SCALP PSORIASIS IMPROVEMENT IN PATIENTS TREATED WITH IXEKIZUMAB No dispute reported 06/30/2026 1187888452
Principal investigator 1 Incyte Corporation $1,879.00 03/19/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566925
Principal investigator 1 Incyte Corporation $1,314.20 03/19/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566939
Principal investigator 1 Eli Lilly and Company $936.10 03/18/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187888846
Principal investigator 1 ABBVIE INC. $6,429.00 03/07/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202460855
Principal investigator 1 Eli Lilly and Company $8,700.00 03/03/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187888844
Principal investigator 1 Incyte Corporation $2,668.00 02/21/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566932
Principal investigator 1 Incyte Corporation $2,286.60 02/21/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566951
Principal investigator 1 Incyte Corporation $1,916.00 02/21/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566956
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $953.78 02/14/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275315
Principal investigator 1 PFIZER INC. $1,283.18 02/11/2025 Non-covered Recipient Entity
Oakland Hills Dermatology PC
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228759429
Principal investigator 1 ABBVIE INC. $5,982.75 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447410
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567031
Principal investigator 1 Incyte Corporation $9.72 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567035
Principal investigator 1 Incyte Corporation $190.62 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567047
Principal investigator 1 Incyte Corporation $114.50 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567055
Principal investigator 1 Incyte Corporation $2.94 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567063
Principal investigator 1 Incyte Corporation $3.43 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567070
Principal investigator 1 Incyte Corporation $13.60 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567081
Principal investigator 1 Incyte Corporation $12.20 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567085
Principal investigator 1 Incyte Corporation $0.44 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567093
Principal investigator 1 Incyte Corporation $33.96 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567104
Principal investigator 1 Incyte Corporation $103.25 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567109
Principal investigator 1 Incyte Corporation $2.04 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567116
Principal investigator 1 Incyte Corporation $29.52 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567122
Principal investigator 1 Incyte Corporation $6.76 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567130
Principal investigator 1 Incyte Corporation $1.40 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567140
Principal investigator 1 Incyte Corporation $3.32 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567150
Principal investigator 1 Incyte Corporation $6.88 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567158
Principal investigator 1 Incyte Corporation $9.45 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567166
Principal investigator 1 Incyte Corporation $1.47 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567170
Principal investigator 1 Incyte Corporation $1.02 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567177
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567186
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567192
Principal investigator 1 Incyte Corporation $104.56 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567201
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567211
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567219
Principal investigator 1 Incyte Corporation $76.92 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567227
Principal investigator 1 Incyte Corporation $24.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567236
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567243
Principal investigator 1 Incyte Corporation $22.29 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567254
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567262
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567269
Principal investigator 1 Incyte Corporation $58.78 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567280
Principal investigator 1 Incyte Corporation $120.06 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567287
Principal investigator 1 Incyte Corporation $43.32 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567295
Principal investigator 1 Incyte Corporation $6.25 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567347
Principal investigator 1 Incyte Corporation $27.75 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567353
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567361
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567368
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567376
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567382
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567392
Principal investigator 1 Incyte Corporation $32.36 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567401
Principal investigator 1 Incyte Corporation $9.90 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567412
Principal investigator 1 Incyte Corporation $48.54 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567427
Principal investigator 1 Incyte Corporation $54.62 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567435
Principal investigator 1 Incyte Corporation $119.08 02/06/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream No dispute reported 06/30/2026 1240567441
Principal investigator 1 Incyte Corporation $52.48 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567304
Principal investigator 1 Incyte Corporation $77.75 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567316
Principal investigator 1 Incyte Corporation $9.33 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567323
Principal investigator 1 Incyte Corporation $4.25 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567335
Principal investigator 1 Incyte Corporation $157.44 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567343
Principal investigator 1 Incyte Corporation $93.30 02/05/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240567420
Principal investigator 1 AstraZeneca UK Limited $21,000.00 01/27/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy No dispute reported 06/30/2026 1185543554
Principal investigator 1 Incyte Corporation $2,007.00 01/24/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566896
Principal investigator 1 Incyte Corporation $1,301.40 01/24/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566902
Principal investigator 1 SANOFI US SERVICES INC. $1,755.00 01/17/2025 Non-covered Recipient Entity
Quality Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101342
Principal investigator 1 SANOFI US SERVICES INC. $74.25 01/17/2025 Non-covered Recipient Entity
Quality Clinical Research Inc
Registry to characterize the patients who receive Dupixent for PN in a real-world setting No dispute reported 06/30/2026 1226101348
Principal investigator 1 Eli Lilly and Company $11,600.00 01/13/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY PC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187885102
Principal investigator 1 Incyte Corporation $800.00 01/08/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566909
Principal investigator 1 Incyte Corporation $9,500.00 01/08/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566918
Principal investigator 1 Incyte Corporation $1,500.00 01/08/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566965
Principal investigator 1 Incyte Corporation $2,500.00 01/08/2025 Non-covered Recipient Entity
OAKLAND HILLS DERMATOLOGY
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis No dispute reported 06/30/2026 1240566977